WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced data from a Phase 1b combination therapy trial with ARQ 501 and docetaxel that support previously announced findings demonstrating clinical tolerability and promising signs of anti-tumor activity in cancer patients with a range of advanced solid tumors who had failed prior treatments with a range of anti-cancer therapies.
